Projected Long-Term Survival High for Patients with Advanced Non–Small-Cell Lung Cancer Treated with Pembrolizumab

TOP - May 2017, Vol 10, No 2 - Lung Cancer
Chase Doyle

Orlando, FL—Durability of benefit (ie, the possibility for sustained remission in patients with previously incurable disease) is already one of the hallmarks of immunotherapy. According to a recent statistical analysis, however, this durability even exceeded expectations.

Based on data from multiple KEYNOTE clinical trials, Matthew D. Hellmann, MD, Medical Oncologist, Memorial Sloan Kettering Cancer Center and Weill Cornell Medical College, New York, estimates that ≤25% of patients with advanced non–small-cell lung cancer who received pembrolizu­mab will achieve long-term survival. When compared with a long-term survival rate of just 3% to 4% for patients who received chemotherapy, these findings underscore the “remarkable step forward” made with immunotherapy, Dr Hellmann noted.

“We’re cautious to use these sorts of words, but these outcomes really do start to approach the concept of cure for patients with advanced cancer. These aren’t just numbers on a curve or dots on a plot; these are patients that we see in the clinic who are continuing to do well years after being given pembrolizumab,” he said.

As Dr Hellmann reported at the 2017 Society for Immunotherapy of Cancer Clinical Immuno-Oncology Symposium, whereas cytotoxic chemotherapy or tyrosine inhibitors provide some meaningful anticancer responses, progression invariably occurs. With the advent of immunotherapies, however, the survival curve for patients with several types of advanced cancers has fundamentally changed.

“Using conventional modeling, in which we assume that everyone progresses, the proportion of patients with long-term survival is potentially zero. In the context of immunotherapy, however, progression and death is not necessarily inevitable, and long-term survival models must consider the possibility of a plateaued survival when estimating outcomes further out,” said Dr Hellmann.

Using medium-term survival data from KEYNOTE-001 and KEYNOTE-010 studies, in which previously treated patients with PD-L1–positive non–small-cell lung cancer were given pembrolizumab, the investigators projected the percentage of patients who would achieve long-term survival.

“Our approach was to take an initial estimate of long-term survival in patients treated in KEYNOTE-001 and then independently examine data from KEYNOTE-010 to validate the reproducibility of that estimate,” Dr Hellmann explained.

With this model, based on KEYNOTE-001 data, it was estimated that approximately 25.4% of patients receiving pembrolizumab therapy would survive long-term. Further analysis of KEYNOTE-010 cutoff data, which included 6 additional months of patient follow-up, showed a long-term survival estimate of approximately 21.5%. By contrast, docetaxel chemotherapy has an estimated long-term survival rate of 3% to 4% in the same patient population.

“The lives and the expectations of these patients has remarkably changed,” said Dr Hellmann, who emphasized that this is just the beginning of research into immunotherapy’s survival benefit.

“We’ve got a lot of work to do in understanding with precision who these people are in the tail of the curve so that we can get them the right therapy from the start,” he concluded.

Related Items
A Home Run for Pembrolizumab plus Chemotherapy Combination in Newly Diagnosed Metastatic Non–Small-Cell Lung Cancer
Phoebe Starr
TOP - August 2018, Vol 11, No 2 published on August 3, 2018 in Lung Cancer
Alunbrig (Brigatinib) Approved for Metastatic NSCLC with ALK Mutation
Lisa A. Raedler, PhD, RPh, Medical Writer
2018 Third Annual Oncology Guide to New FDA Approvals published on May 9, 2018 in FDA Approvals, News & Updates, Lung Cancer
ASH Recaps “Phenomenal” Year for Acute Myeloid Leukemia Drug Approvals
Chase Doyle
TOP Web Exclusives published on April 9, 2018 in Leukemia
Which Combination Immunotherapies to Use, and When? High Response Rates, but Serious Toxicity Remains a Concern
Chase Doyle
TOP Web Exclusives published on April 9, 2018 in Immunotherapy
CheckMate-227 Meets Co-Primary End Point of PFS with Nivolumab/Ipilimumab Combination in NSCLC, Confirms TMB as Viable Biomarker
TON Web Exclusives published on March 16, 2018 in Lung Cancer
Treatment Paradigm Shift in ALK-Positive NSCLC Raises Further Questions Regarding ALK Inhibitor Sequencing
TON Web Exclusives published on March 16, 2018 in Lung Cancer
FDA Grants Orphan Drug Designation to Seribantumab, an Investigational Treatment for Heregulin-Positive NSCLC
TON Web Exclusives published on March 16, 2018 in Lung Cancer
Three Leading Medical Societies Update Molecular Testing Guideline for Lung Cancer TKI Treatment
TON Web Exclusives published on March 16, 2018 in Lung Cancer
Brigatinib May Prolong Survival After Progression of Crizotinib-Refractory, ALK-Positive NSCLC
TON Web Exclusives published on March 16, 2018 in Lung Cancer
Oral Multiple Myeloma Medication Linked to Decreased Productivity Loss
Chase Doyle
TON - March 2018, Vol 11, No 1 published on March 9, 2018 in Conference Correspondent, ASH, Multiple Myeloma
Last modified: May 10, 2017